My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Merck & Co (NY:MRK)

122.26 +0.40 (+0.33%)

Official Closing Price Updated: 7:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

99 100 Next >

CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines ↗

October 24, 2024

The CDC recommends expanding pneumococcal vaccine eligibility to adults aged 50 and above, impacting disease prevention with Pfizer and Merck's vaccines.

Via Benzinga

3 Absurdly Cheap Stocks That Pay High Dividends ↗

October 24, 2024

These stocks are trading at less than 15 times their expected future profits.

Via The Motley Fool

800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio ↗

October 23, 2024

EF Hutton rates ImmunityBio (IBRX) as a Buy with a $30 target. Anktiva shows promise in cancer treatment, boosting response rates and survival outcomes.

Via Benzinga

Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise ↗

October 22, 2024

There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle.

Via Talk Markets

(MRK) - Analyzing Merck & Co's Short Interest ↗

October 22, 2024

Via Benzinga

Is NYSE:MRK a Good Fit for Dividend Investing? ↗

October 14, 2024

Why the dividend investor may take a look at MERCK & CO. INC. (NYSE:MRK).

Via Chartmill

A Closer Look at Merck & Co's Options Market Dynamics ↗

October 11, 2024

Via Benzinga

Demystifying Merck & Co: Insights From 8 Analyst Reviews ↗

October 03, 2024

Via Benzinga

Exploring The Competitive Space: Merck & Co Versus Industry Peers In Pharmaceuticals ↗

October 03, 2024

Via Benzinga

Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks ↗

October 21, 2024

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable success...

Via Benzinga

After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment ↗

October 18, 2024

Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory results from the TROPiCS-04 study. However, the decision does not impact...

Via Benzinga

Merck Virus Treatment Shows 60.4% Effectiveness, Reduces Certain Infections In Infants ↗

October 18, 2024

Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV.

Via Benzinga

Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment ↗

October 15, 2024

The company could have a long path ahead to reimbursement and, ultimately, sales.

Via Investor's Business Daily

Up 700% This Year, Is It Too Late to Invest in This Stock? ↗

October 15, 2024

The shares have experienced a pullback in the past couple of weeks.

Via The Motley Fool

2 Incredibly Cheap Big Pharma Stocks to Buy Now ↗

October 12, 2024

There's doubtlessly some coming uncertainty for both, but the prices are right.

Via The Motley Fool

18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker' ↗

October 10, 2024

Goldman Sachs identifies 18 stocks for potential earnings upside and advises options-based strategies in a volatile market. 10% upside for S&P 500.

Via Benzinga

Topics Stocks

Personalized Treatment And Immunotherapy Are Pharma's Newest Weapons Against Cancer ↗

October 10, 2024

On Sunday, The Guardian issued an article that spoke of a UK study that could transform how cancer is treated. The large-scale clinical project assessed how personalized cancer therapies could...

Via Benzinga

NYSE:MRK stands out as a stock that provides good value for the fundamentals it showcases. ↗

October 09, 2024

When you look at MERCK & CO. INC. (NYSE:MRK), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

Via Chartmill

Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock' ↗

October 09, 2024

Target (TGT) stock recommended by Jim Cramer at current price with plans to buy more. Merck (MRK) and Unity Software (U) also discussed.

Via Benzinga

Topics Artificial Intelligence

Merck's Mumps Vaccine Controversy: Class-Action Lawsuit Alleges Anticompetitive Behavior, Court Shields From Liability ↗

October 08, 2024

Merck faces a class-action lawsuit over alleged misrepresentation of its mumps vaccine potency, claiming anticompetitive practices to maintain market dominance. Despite ethical concerns, the court...

Via Benzinga

Topics Lawsuit

Merck Touts Phase 3 Success For $20B Cancer Drug Keytruda In Untreated Head And Neck Cancer Patients ↗

October 08, 2024

Merck's Keytruda (pembrolizumab) met primary endpoint of event-free survival (EFS) in Phase 3 trial for newly diagnosed head and neck cancer patients.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

October 07, 2024

Via Benzinga

2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts ↗

October 07, 2024

The investment bank analysts who follow these stocks think they can soar even further, with some caveats.

Via The Motley Fool

Is It Time to Buy September's Worst-Performing Dow Jones Stocks? ↗

October 05, 2024

They may technically be blue chips, but that doesn't necessarily make them your best bets at their discounted prices.

Via The Motley Fool

Topics Stocks

Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses ↗

October 04, 2024

Thermo Fisher's Greenville facility, one of the largest in the U.S., has faced repeated FDA regulatory violations. Key concerns include contamination prevention and inadequate equipment sterilization...

Via Benzinga

Could Summit Therapeutics Become the Next Merck? ↗

October 04, 2024

Recent developments are forcing comparisons between these two drugmakers.

Via The Motley Fool

Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers. ↗

October 03, 2024

Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.

Via Investor's Business Daily

Topics Stocks

The Covid Era Tech Promises To Reinvent Cancer Treatment ↗

October 01, 2024

Pfizer Inc (NYSE: PFE) made a promise to outdo cancer, joining its Covid vaccine-peer, Moderna Inc (NASDAQ: MRNA) in turning to oncology for its next growth story.

Via Benzinga

How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

October 01, 2024

How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Via News Direct

2 High-Potential Growth Stocks You Shouldn't Overlook ↗

September 29, 2024

These two growth stocks have plenty of room to run.

Via The Motley Fool

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.